Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
iktos logo — Artificial intelligence for new drug design

iktos

Artificial intelligence for new drug design

Founded 2016 France France 85 employees Series A Total: $18.90M AI, Biotechnology +2

General Information

Company Name iktos
Founded Year 2016
Location France France
Founders / Decision Makers
Team member
Employees 85
Industries AI, Biotechnology, Health Care +1
Funding Stage Series A
Business Model B2B, SaaS, Platform
Revenue Model Subscription, Project Based, Licensing
Social

BounceWatch is an independent company data service, not affiliated with iktos. To contact iktos, visit iktos.ai.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does iktos compare?

A PDF of iktos and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting iktos soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About iktos

Iktos, founded in 2016 and headquartered in France, stands out as a leader in the convergence of AI and biotechnology for drug discovery. Its slogan, "Artificial intelligence for new drug design," encapsulates its mission to leverage cutting-edge technologies for medicinal chemistry.

The company's proprietary generative AI solutions, offered through the Makya™ and Spaya™ platforms, enhance small molecule drug discovery, boosting accuracy and efficiency. Through its strategic SaaS model, Iktos collaborates with pharma giants to expedite R&D processes.

The company's notable milestones include a €15.5M Series A financing round in March 2023 and the July 2024 acquisition of Synsight, enhancing its capabilities in targeting PPI and RPI. The recent $2.50M grant from the European Innovation Council reinforces investor confidence in its innovative approach.

Business keywords: Drug Design, Medicinal Chemistry, Generative AI, Chemoinformatics, Robotics Automation, SaaS Software, Molecular Modeling, Oncology, Retrosynthesis, Protein-Protein Interactions, RNA-Protein Interactions, Synthesis Automation, Pharmaceutical R&D, Lead Optimization

Services & Products

Generative AI Platform (Makya)
AI-Driven Retrosynthesis (Spaya)
Automated Drug Development Pipeline
Autonomous Lab Robotics

Target Customers

Pharmaceutical Companies Biotech Firms Academic Institutions Medicinal and Computational Chemists Drug Discovery Teams

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $2.50M 1
European Innovation Council
European Innovation Council
01 Oct 2024
Series A €15.50M 3
The Group Ventures Omnes Capital M Ventures
The Group Ventures, Omnes Capital +1
01 Mar 2023
Debt Financing €900.00K 1
Bpifrance
Bpifrance
01 Jan 2021
Seed Undisclosed -
01 Jan 2019
Support Program Undisclosed 1
AGORANOV
AGORANOV
01 Feb 2018
Support Program Undisclosed 2
HEC Paris, HEC Challenge+
01 Oct 2017
Seed Undisclosed -
01 Jun 2017

Latest News

View All
AWS names 12 European AI startups mapping oceans, diagnosing leukaemia, and predicting airstrikes — Thenextweb
AWS names 12 European AI startups mapping oceans, diagnosing leukaemia, and predicting airstrikes
Thenextweb Mar 18, 2026

iktos Alternatives & Competitors

View All Alternatives
iktos vs
Terray Therapeutics
Terray Therapeutics United States

Everything small molecule drug discovery should be.

Series B
142 employees
AI, Biopharma
Compare iktos vs Terray Therapeutics
iktos vs
Variational AI
Variational AI Canada

State-of-the-art generative AI for small molecule drug discovery

Seed
23 employees
AI, Biotechnology
iktos vs
Sibylla Biotech
Sibylla Biotech Italy

Fold the future

Series A
44 employees
Biotechnology, Health Care
Also compare with: iktos vs Genesis Molecular AI Genesis Molecular AI iktos vs Insilico Medicine Insilico Medicine iktos vs molecule.one molecule.one View all alternatives

FAQ About iktos

Artificial intelligence for new drug design
iktos was founded in 2016.
iktos is headquartered in France.
iktos operates in AI, Biotechnology, Health Care and Pharmaceutical. Its work centres on Drug Design, Medicinal Chemistry, Generative AI and Chemoinformatics. Its customers include Pharmaceutical Companies, Biotech Firms and Academic Institutions.
iktos has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Project Based and Licensing.
iktos has approximately 85 employees.
iktos has completed 7 funding rounds, raising a total of $18.90M. The latest funding stage is Series A.
iktos offers: Generative AI Platform (Makya), AI-Driven Retrosynthesis (Spaya), Automated Drug Development Pipeline, Autonomous Lab Robotics.
Top alternatives and competitors to iktos include Terray Therapeutics, Variational AI, Sibylla Biotech, Synfini, Inc., X-37. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
iktos and Terray Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for iktos, https://bouncewatch.com/company/iktos, updated 20 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes